Curbing attacks through proactive measures

Migraines can significantly reduce the quality of life of those affected. Early treatment is therefore advisable if the diagnosis is confirmed. Migraine therapy can be divided into three groups: Acute therapy, prophylaxis, non-drug measures. Monoclonal antibodies against CGRP and the CGRP receptor are now well established for long-term drug prophylaxis. The new up-and-coming generation of migraine drugs includes Ditane and Gepante.